Anonymous7 days ago
A phase 3 clinical trial called RASolute 302 found that daraxonrasib, an oral RAS inhibitor made by Revolution Medicines, nearly doubled median overall survival in previously treated metastatic pancreatic cancer patients (13.2 vs. 6.7 months) compared to chemotherapy. Published in the New England Journal of Medicine and presented at ASCO 2026, the results represent the largest survival gain in pancreatic cancer treatment in decades — but independent oncologists caution that toxicity concerns, unanswered questions about long-term durability, and uncertain pricing and global access temper the enthusiasm.